Skip to main content

Table 1 Patient characteristics

From: Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [18F]DCFPyL-PET: comparison to [18F]fluorocholine-PET

  [18F]FCH (n = 23) [18F]DCFPyL (n = 19) P value
Age (y) 61.1 ± 6.9 (49–76)* 62.4 ± 4.7 (50–67)* 0.58
Weight (kg) 93.3 ± 14.3 (67–122)* 86.4 ± 17.1 (30–109)* 0.46
Height (cm) 175.7 ± 5.0 (168–185)* 177.1 ± 6.3 (165–191)* 0.37
PSA (ng/mL) 5.9 ± 3.4 (0.9–15.0)* 8.4 ± 5.8 (3.5–25.5)* 0.42
Histology—n(%) 1.00
 Adenocarcinoma 23 (100) 19 (100)  
pT stage—n(%) 0.93
 T2a 1 (4.3) 0 (0)  
 T2c 12 (52.2) 11 (57.9)  
 T3a 5 (21.7) 7 (36.8)  
 T3b 5 (21.7) 1 (5.3)  
pN stage—n(%) 0.79
 N0 19 (82.6) 19 (100)  
 N1 1 (4.3) 0 (0)  
 NX 3 (13.0) 0 (0)  
Gleason score—n(%) 0.94
 6 (3 + 3) 2 (8.7) 1 (5.3)  
 7 (3 + 4) 17 (69.6) 16 (84.2)  
 7 (4 + 3) 4 (17.4) 2 (10.5)  
 9 (5 + 4) 1 (4.3) 0 (0)  
Proportion of prostate involved by tumour (%) 14.3 ± 15.5 (1–80)* 13.7 ± 7.7 (5–30)* 0.49
  1. Data are number of patients, with the percentage in parentheses unless otherwise indicated
  2. FCH, fluorocholine; DCFPyL, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid; PSA, prostate-specific antigen
  3. *Data are means ± standard deviation, with the range in parentheses